10-Q: Sharps Technology Reports Q3 2024 Results: Revenue Remains Elusive Amidst Restructuring and Legal Challenges

Sharps Technology reported no revenue for the third quarter of 2024, alongside a net loss, while navigating ongoing legal issues and strategic shifts.

Summary

• Sharps Technology, a pre-revenue medical device company, reported no revenue for the three and nine months ended September 30, 2024.
• The company's net loss for the three months ended September 30, 2024, was $1.685 million, and for the nine months ended September 30, 2024, the net loss was $4.770 million.
• Operating expenses for the nine months totaled $5.780 million, with research and development at $523,347 and general and administrative expenses at $5.257 million.
• The company's working capital as of September 30, 2024, was $67,820, which is not expected to be sufficient to fund operations for the next 12 months.
• Sharps Technology is dependent on raising sufficient financing to commercialize its products and continue as a going concern.
• The company completed a 1 for 22 reverse stock split on October 16, 2024.
• The company has been involved in several legal proceedings, including lawsuits from Barry Berler and Plastomold Industries Ltd.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with no revenue, significant losses, and insufficient working capital. The company is also facing multiple legal challenges and delays in product commercialization. While there are some positive developments, such as the supply agreement with Stericare, the overall sentiment is negative due to the company's financial instability and operational challenges.

Positives

• The company entered into a supply agreement with Stericare Solutions for 520 million units of Sologard syringes, with expected revenues exceeding $50 million.
• The company has a new logistics services agreement with Owens and Minor to replace Nephron's distribution services.
• The company successfully regained compliance with Nasdaq listing rules on November 5, 2024.
• The company completed a debt financing agreement for $4.375 million, providing much needed capital.

Negatives

• The company has not generated any significant revenue from the sale of syringe products.
• The company's working capital is insufficient to fund operations for the next 12 months.
• The company is facing multiple legal challenges.
• The company has incurred significant net losses since its inception.
• The company's ability to continue as a going concern is dependent on raising sufficient financing.
• There have been delays in the commercialization of the Sharps Provensa product line.
• A $1 million deposit related to an asset purchase agreement was forfeited.

Risks

• The company's ability to continue as a going concern is dependent on raising sufficient financing.
• The company is facing legal challenges that could result in significant costs and diversion of management resources.
• The company has not generated any significant revenue and is dependent on future sales.
• Delays in the commercialization of the Sharps Provensa product line could impact future revenue.
• The company's working capital is insufficient to fund operations for the next 12 months.
• The company's stock price has been volatile and could be impacted by future events.

Future Outlook

The company intends to finance its commercialization activities and working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements. The company is working towards a further amendment of the Asset Purchase Agreement. The closing of the Asset Purchase Agreement is contingent on obtaining further amendments and the necessary financing. There can be no assurance that the closing of the asset sale will occur.

Management Comments

• The company continues to be in discussions with healthcare companies and distributors for sales of our disposable syringe and prefillable syringe products.
• We have produced commercial quantities of our products and built inventory to support orders in late 2024 and in 2025.
• The company will continue working to amend the terms of the NPC Agreement and Nephron Agreement, based on the Amended Asset Purchase Agreement below dated May 20, 2024.

Industry Context

The medical device industry is highly competitive, and Sharps Technology is facing challenges in commercializing its products. The company's focus on safety syringes aligns with a growing demand for safer medical devices, but the company needs to overcome its financial and legal hurdles to succeed.

Comparison to Industry Standards

• Sharps Technology's lack of revenue is a significant deviation from industry norms for companies that have been operating for several years.
• Many medical device companies at a similar stage of development would have some level of product sales or partnerships in place.
• The company's high operating expenses and reliance on external funding are also concerning when compared to industry benchmarks.
• The legal challenges faced by Sharps are not uncommon in the industry, but the number and severity of the issues are notable.
• Compared to companies like Becton Dickinson or Medtronic, Sharps is significantly behind in terms of revenue generation and market presence.
• Companies like West Pharmaceutical Services or Gerresheimer, which focus on medical packaging and drug delivery systems, have established revenue streams and a more stable financial position.
• The company's reliance on equity financing is also a concern, as it can dilute existing shareholders and may not be sustainable in the long term.

Legal Proceedings

• Barry Berler, a co-founder and former Chief Technology Officer of the Company, commenced a lawsuit against the Company.
• Berler filed a demand for arbitration and statement of claim under the commercial arbitration rules of the American Arbitration Association (AAA).
• Plastomold Industries Ltd. commenced a lawsuit against the Company.

Related Party Transactions

• As of September 30, 2024 and December 31, 2023, accounts payable and accrued liabilities include $ 152,500 and $ 32,974 , respectively, payable to officers and directors of the Company.

Stakeholder Impact

• Shareholders are at risk due to the company's financial instability and potential dilution from future equity offerings.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers and suppliers may be concerned about the company's ability to fulfill orders and meet its obligations.
• Creditors may be at risk due to the company's financial instability and potential inability to repay debts.

Next Steps

• The company will continue working to amend the terms of the NPC Agreement and Nephron Agreement.
• The company will continue to work with Roncadelle for product introductions and execution of the Agreement for future sales.
• The company will continue to seek funding through equity offerings and/or debt financing opportunities.
• The company will continue to defend itself vigorously in connection with the legal claims.

Key Dates

Keywords

medical devices, safety syringes, manufacturing, distribution, revenue, net loss, working capital, legal proceedings, reverse stock split, debt financing, equity offering, warrants, Stericare Solutions, Roncadelle, Nasdaq